Clinical trial
High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous…
NCT00002818 · Virginia Commonwealth University, Other · Completed
Key facts
| NCT number | NCT00002818 |
|---|---|
| Title | High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies |
| Official title | Phase I and Clinical Pharmacokinetic De-Escalation Study of 2'-Deoxycitidine Administered as a Continuous Infusion in Conjunction With a Continuous Infusion of High-Dose ARA-C in Patients With Refractory Acute Myelogenous Leukemia |
| Lead sponsor | Virginia Commonwealth University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | cytarabine, deoxycytidine |
| Enrollment | 15 |
| Start date | Feb 1, 1995 |
| Primary completion | Feb 1, 2001 |
| Completion | Feb 1, 2001 |
| First posted | Apr 22, 2004 |
| Last update posted | Dec 14, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: